Wave Life Sciences exits its May earnings week battered — down 10% in a single session and nearly 10% on the week — with analysts racing to reprice a stock that has lost more than half its value this year.
The post-earnings damage is the story this week. The company reported on May 18 and dropped 9.3% the following day. That follows a softer reaction to the May 8 event, where the stock fell 2.3% on the day and extended losses to 6.5% over the subsequent five days. The pattern is consistent: recent catalysts have pushed the stock lower, not higher, and the one-month decline of 18% reflects the cumulative weight of that. At $6.14, the stock is trading well below even the most recently trimmed analyst targets.
The Street remains uniformly bullish on rating — every active analyst carries a Buy or Overweight — but the speed at which targets are being cut tells a different story. This week, Wells Fargo raised its target marginally from $13 to $14 while holding Overweight, a rare upward move. But HC Wainwright cut from $18 to $13 on Tuesday, the second trim from that firm in five weeks. Citigroup lowered to $24 from $30 earlier this month. Truist made the most dramatic move in late April, dropping its target from $50 to $15. The mean price target now sits at $21.94 — more than three times the current price. That gap is wide enough to warrant scrutiny: either the Street sees something the market doesn't, or targets are lagging the pace of deterioration. The consensus hold on Buy ratings while continuously cutting numbers is a classic pattern of analysts reluctant to pull ratings on a clinical-stage biotech they believe in longer-term.
The options market, for its part, is leaning bullish — sharply so. The put/call ratio collapsed to 0.16 this week, more than two standard deviations below its 20-day mean of 0.60. That is close to the 52-week low of 0.05, and marks a dramatic continuation of the call-heavy positioning flagged in last week's note. Options traders are not hedging here — they are expressing directional conviction on the upside. Short interest, meanwhile, has held near the levels reached last week at 10.8% of free float, edging up another 0.8% on the day. The 34% build over the past month remains intact. Crucially, the borrow market has not tightened at all despite that accumulation: availability remains at 1,471% — still an exceptionally loose lending pool, with roughly 99.6 million shares available to borrow against 18 million currently short. Cost to borrow has actually eased to 0.44% annualised, down 6% on the week. Bears face no friction.
The ownership picture adds one genuinely interesting data point. RA Capital Management — the top institutional holder with just over 14% of shares — made a concentrated cluster of purchases in late March, buying roughly 8.8 million shares across four days at prices between $6.06 and $6.50. Those trades now sit at or below cost. RA Capital is also a board member and a 10% owner, making this a strategic holder rather than a momentum investor. The fact that they bought aggressively at these exact price levels, and that the stock has failed to sustain any recovery since, frames the current level as one the firm has already tested its conviction on.
The next scheduled earnings event is August 3. Between now and then, the setup to watch is whether the divergence between a call-heavy options market and a building short interest position begins to resolve — and whether the clinical pipeline delivers any data that would give analysts a basis to defend targets that currently sit three times above where the stock is trading.
See the live data behind this article on ORTEX.
Open WVE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
